NuQu is an injection of young cartilage cells into intervertebral discs that can be performed in an outpatient setting, with patients able to go home an hour after the treatment.
The trials are sponsored by St. Louis-based ISTO Technologies and will examine the safety and efficacy of the treatment, which is designed as a next line of response for patients who have had lower back pain for at least six months, have never had lower back surgery and who do not respond to standard-of-care treatment for back pain caused by disc degeneration.
More Articles on Spine:
67% of Physicians See No Financial Return from ACOs
Spine Care for All Patients: Q&A With Dr. Christopher Kauffman of Premier Orthopaedics
8 Inexpensive Ideas to Improve Patient Experience at Spine Centers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.